How lung adenocarcinoma spreads and hides from the immune system
Official title: Mediators of Lung Adenocarcinoma Metastasis
Funded at Sloan-Kettering Inst Can Research · NIH-11265091 · Data updated 2026-11-12
This work looks at the specific lung cancer cells that let tumors spread and survive so better ways to prevent relapse can be found.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 1, 2007 |
| Project end | April 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $348,983 |
| NIH project number | 2P01CA129243-16A1 |
| Project ID | NIH-11265091 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with lung adenocarcinoma—particularly those with metastatic or recurrent disease or those able to donate tumor tissue or blood—would be most relevant to this research.
✕Less likely to help
Patients with cancers other than lung adenocarcinoma or those unwilling to provide samples are unlikely to benefit directly from this specific project, and it does not promise immediate new treatments.
What this research studies
Researchers study the particular lung adenocarcinoma cells that can break away, survive many stresses, and later regrow tumors, using both human tumor samples and mouse models that mimic patient disease. They track cell states using markers such as SOX2 and SOX9 and study how some cells enter a quiet, immune‑hiding state by lowering immune signals like STING, NK ligands, and MHC‑II. Lab experiments and animal models are used to follow which cells resist therapy and cause metastasis, with the goal of finding points to block relapse and improve treatment responses.
Why it matters
Potential benefit: If successful, this work could lead to therapies or tests that reduce metastatic relapse and make treatments work longer for people with lung adenocarcinoma.
How similar studies have gone: Previous studies have identified metastasis‑initiating cell features and immune‑evasion behaviors, but turning those findings into widely available patient treatments remains at an early, developing stage.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Massague, Joan — Sloan-Kettering Inst Can Research
- Study coordinator: Massague, Joan
Related research
Other NIH-funded projects on the same topics.
-
Targeting a cancer pathway to stop metastasis in SMARCA4-deficient lung cancer
This grant aims to understand and interrupt a key pathway that drives spread of a specific type of lung cancer in people whose tumors have SMARCA4 mutations.
-
Stopping the spread of lung cancer in patients with a specific gene change
This research aims to find new ways to prevent lung cancer from spreading in patients who have a particular genetic change called SMARCA4 deficiency.
-
Investigating how a specific pathway affects the spread of lung cancer lacking a key protein.
This study is looking at how a missing protein in a type of lung cancer affects its ability to spread, and it hopes to find new ways to treat patients by understanding the genetic changes involved.
-
Understanding a highly flexible cell state in lung cancer that worsens outcomes
A doctor-scientist at Cedars-Sinai wants to learn how a highly adaptable lung cancer cell state drives disease progression and resistance to therapy, using models that resemble human tumors.
-
Breaking cytokine loops in LKB1-mutant lung cancer and the immune system
A researcher at NYU School of Medicine is studying why a common lung cancer subtype with a specific mutation doesn’t respond well to current immunotherapy, with the aim of finding new ways to improve treatment.
-
Lung Adenocarcinoma: From Genome Changes to New Therapies
This NIH grant supports research on lung adenocarcinoma to better understand its genome changes and translate that knowledge into better diagnosis and treatments for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.